Information om | Engelska ordet RANIBIZUMAB

Exempel på hur man kan använda RANIBIZUMAB i en mening

• Drugs such as aflibercept, bevacizumab, ranibizumab, and pegaptanib can inhibit VEGF and control or slow those diseases.
• In 2005 bevacizumab and ranibizumab intravitreal injections for the treatment of wet-AMD caused a rise in injections to 252,000.
• In the United States, ranibizumab is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
• In a press release issued by ISTA Pharmaceuticals, which has a strong interest in the success of the drug, it was claimed that Grant demonstrated a significant decrease in the number of treatments of ranibizumab (Lucentis) needed for the treatment of choroidal neovascularization secondary to age-related macular degeneration by the concomitant administration of bromfenac (Xibrom).
• The use of the intravitreal anti VEGF agents namely bevacizumab and ranibizumab have been described recently.
• They can involve monoclonal antibodies such as bevacizumab, antibody derivatives such as ranibizumab (Lucentis), or orally-available small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF receptors rather than the VEGFs).
• Six extra medications, namely triamcinolone acetonide, ranibizumab (Lucentis), aflibercept (Eylea/Zaltrap), dexamethasone, ocriplasmin and fluocinolone acetonide were approved for this injection by the end of 2014.
• Compared to two similar anti-VEGF intravitreal drugs, ranibizumab and aflibercept, conbercept has been shown to be the most cost-effective option for treatment of wAMD in China.

Förberedelsen av sidan tog: 4 085,24 ms.